Researchers have shed light on how a class of medications that help regulate blood sugar for patients with type 2 diabetes can also protect from heart disease.

The findings published in the journal ‘cell metabolism’focus on the effect of diabetes medication-empagliflozin-on cell repair in blood vessels and the resulting risk of heart disease.

Large scale clinical trials give clear indication/evidence that SGLT2 inhibitors can also protect patients who have diabetes from heart disease.

_Health_